Search

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management

Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management. Click here to find out more information.

COVID-19 Relief Efforts in China

Since the outbreak of the Coronavirus disease in China in late January, Boehringer Ingelheim has quickly decided to make a number of donations. Read more.

My.Making More Health Website

My.Making More Health, our platform for disadvantaged communities goes live, providing materials on health prevention for all. Click here to learn more.

garbage game

Learn more about marine pollution and find out how long it takes for garbage to dissolve in the oceans.

Stroke Risk Factors Symptoms

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Find out more about risk factors and symptoms.

What can the patient do?

Be aware and know your source.

Innovation, animal well-being and productivity

Boehringer Ingelheim reinforces its focus on innovation, animal well-being and productivity. Click here to learn and find out more information.

1988-2015

Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.

The Supplier Code of Conduct

Read about Boehringer Ingelheim's expectations towards its suppliers on ethical behaviour, integrity, professionalism and common business requirements.

Supporting Fundappas

Fundappas is the first school of guide and assistance dogs in Uruguay. We support Fundappas to improve the quality of life of dogs and people. Learn more.

Rare Diseases: Rare but not alone

We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies. Click here to find out more about our work.

Our-position

12 years ago, several leading German companies including Boehringer Ingelheim came together to launch Afrika Kommt! Learn more about it here.

COVID-19 Learning from the pandemic

Online training options develop vets and other animal health professionals’ skills helping them overcome movement restrictions to thrive around the globe.

COVID-19 Global Access Commitment with Gates Foundation

Boehringer Ingelheim commits to provide global access to COVID-19 therapeutics by signing a communiqué with the Bill & Melinda Gates Foundation.

Lyon

Boehringer Ingelheim has a research and production network across the globe. Click here to read and find out information about our Lyon site.

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany. Click here to find out and learn more about our headquarters.

COVID-19 India - supporting community during the pandemic

Boehringer Ingelheim India was amongst the first few companies supporting local authorities in Maharashtra in this crisis. Click here to learn more.

COVID-19 Boehringer Ingelheim Singapore JSS donations

Boehringer Ingelheim Singapore donates government payouts for more good causes, giving back to patients and animals who need it the most. Learn more.

Partnering for innovation and growth

In this interview Dr Frerich de Vries talks about why partnerships are one of the key areas of interest for Boehringer Ingelheim and more. Learn more.

Production Insights

Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals. Click here to learn and find out more.

Our Commitment

We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals. Find out more.

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners. Click here to learn more.

Boehringer Ingelheim announces appointment of Gagandeep Singh as Managing Director and Head of Human Pharma for India

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.

Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine

Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine. Click here to find out and learn more information.

About Us

Human Health

Animal Health